DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06182618

Unknown

Retrospective Analysis for Patients With Metabolic Syndrome

Retrospective Analysis of Outpatient Intervention Effects in Patients With Metabolic Syndrome

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

400

estimated

Study population

Metabolic syndrome, Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Weight

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06182618
Org study ID2023-1042

Timeline

Milestones

Study start2023-06-01actual
Study first posted2023-12-27actual
Last update posted2023-12-27actual
Primary completion2024-01-01estimated
Study completion2024-01-01estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Metabolic syndromeObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersAccepted
Sampling methodProbability sample

Study population text

This was a retrospective study of the weight loss effect in 1 to 3 months in overweight or obese individuals at the department of clinical nutrition in the Second Affiliated Hospital of Zhejiang University, School of Medicine in China between 1 January 2020 and 1 Janu-ary 2024.

Inclusion criteria

• individuals who had at least a 2 follow up visits with a BMI of 24 or more with the pri-mary goal of losing weight.

Exclusion criteria

•patients did not follow-up on a monthly basis;
•patients followed-up less than 1 times within 3 months;
•patients having incomplete data;
•patients changing their interventions during fol-low-ups

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

3 endpoints
Primary/protocol endpoint

weight

Time frame:0month/1month/2months/3 months

descriptive, improvement

Secondary/protocol endpoint

visceral fat area(VFA)

Time frame:0month/1month/2months/3 months

Visceral fat, change

change from baseline, improvement

Secondary/protocol endpoint

skeletal muscle mass(SMM)

Time frame:0month/1month/2months/3 months

Lean mass

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.